MicroRNA expression in exhaled breath condensate differentiates between asthma and chronic obstructive pulmonary disease.

IF 3.7 4区医学 Q1 BIOCHEMICAL RESEARCH METHODS

Journal of breath research Pub Date : 2025-05-14 DOI:10.1088/1752-7163/add0d3

Bijay Pattnaik, Sunil Bangaru, Divyanjali Rai, Jaya Tak, Naveen Bhatraju, Seetu Kashyap, Jyoti Kumari, Umashankar Verma, Geetika Yadav, R S Dhaliwal, Saurabh Mittal, Pawan Tiwari, Vijay Hadda, Karan Madan, Anurag Agrawal, Randeep Guleria, Anant Mohan

{"title":"MicroRNA expression in exhaled breath condensate differentiates between asthma and chronic obstructive pulmonary disease.","authors":"Bijay Pattnaik, Sunil Bangaru, Divyanjali Rai, Jaya Tak, Naveen Bhatraju, Seetu Kashyap, Jyoti Kumari, Umashankar Verma, Geetika Yadav, R S Dhaliwal, Saurabh Mittal, Pawan Tiwari, Vijay Hadda, Karan Madan, Anurag Agrawal, Randeep Guleria, Anant Mohan","doi":"10.1088/1752-7163/add0d3","DOIUrl":null,"url":null,"abstract":"Asthma and chronic obstructive pulmonary disease (COPD) have many common clinical characteristics, thus making reliable differentiation between these two challenging. The goal of this study is to determine the clinical value of exhaled breath condensate (EBC) derived miRNAs to discriminate between asthma and COPD. This cross-sectional study included 65 subjects each with asthma (mean/SD age: 39/13 years, Malen/%: 27/42%), COPD (mean/SD age: 61/9 years, Malen/%: 53/81%) and healthy controls (mean/SD age: 34.4/12 years, Malen/%: 50/77%). EBC was collected using R-tubes and 40 EBC samples from each group were used for miRNA profiling. Profiling data was curated and the most highly expressed miRNAs were shortlisted for further validation. Selected microRNAs were subsequently validated using quantitative-PCR in an independent set of 25 subjects from both disease groups. A total of 103 miRNAs were significantly upregulated in the EBC of asthma patients and 97 miRNAs were upregulated in the EBC of COPD patients compared to control group. However, miR-512-3p was downregulated and miR-517c was upregulated in COPD compared with asthma. The top unique miRNAs were shortlisted for further validation. Of these, miR-375 was upregulated in asthma, while miR-297, miR-367 and miR-539 were upregulated in COPD compared with healthy controls. Further, miR-512-3p was down-regulated and miR-517c was upregulated in COPD compared with asthma. The comparison exhibited excellent discriminatory power with 100% differential expression of miR-512-3p and miR-517c secreted by respiratory cells, they could be quantitated in EBC samples and used to differentiate between asthma and COPD.","PeriodicalId":15306,"journal":{"name":"Journal of breath research","volume":"19 3","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of breath research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1088/1752-7163/add0d3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) have many common clinical characteristics, thus making reliable differentiation between these two challenging. The goal of this study is to determine the clinical value of exhaled breath condensate (EBC) derived miRNAs to discriminate between asthma and COPD. This cross-sectional study included 65 subjects each with asthma (mean/SD age: 39/13 years, Malen/%: 27/42%), COPD (mean/SD age: 61/9 years, Malen/%: 53/81%) and healthy controls (mean/SD age: 34.4/12 years, Malen/%: 50/77%). EBC was collected using R-tubes and 40 EBC samples from each group were used for miRNA profiling. Profiling data was curated and the most highly expressed miRNAs were shortlisted for further validation. Selected microRNAs were subsequently validated using quantitative-PCR in an independent set of 25 subjects from both disease groups. A total of 103 miRNAs were significantly upregulated in the EBC of asthma patients and 97 miRNAs were upregulated in the EBC of COPD patients compared to control group. However, miR-512-3p was downregulated and miR-517c was upregulated in COPD compared with asthma. The top unique miRNAs were shortlisted for further validation. Of these, miR-375 was upregulated in asthma, while miR-297, miR-367 and miR-539 were upregulated in COPD compared with healthy controls. Further, miR-512-3p was down-regulated and miR-517c was upregulated in COPD compared with asthma. The comparison exhibited excellent discriminatory power with 100% differential expression of miR-512-3p and miR-517c secreted by respiratory cells, they could be quantitated in EBC samples and used to differentiate between asthma and COPD.

查看原文本刊更多论文

呼气凝析液中MicroRNA的表达可区分哮喘和慢性阻塞性肺疾病。

哮喘和慢性阻塞性肺疾病（COPD）具有许多共同的临床特征，因此对两者进行可靠的鉴别具有挑战性。本研究的目的是确定呼气凝聚物（EBC）衍生的mirna在区分哮喘和COPD方面的临床价值。这项横断面研究包括65名哮喘（平均/SD年龄：39/13岁，Malen/%: 27/42%）、COPD（平均/SD年龄：61/9岁，Malen/%: 53/81%）和健康对照（平均/SD年龄：34.4/12岁，Malen/%: 50/77%）的受试者。采用r管收集EBC，每组40份EBC样本用于miRNA分析。对分析数据进行整理，并将最高表达的mirna列入候选名单以进行进一步验证。随后，在来自两种疾病组的25名独立受试者中，使用定量pcr验证选定的microrna。与对照组相比，哮喘患者EBC中有103个mirna显著上调，COPD患者EBC中有97个mirna上调。然而，与哮喘相比，miR-512-3p在COPD中下调，miR-517c上调。最独特的mirna被列入候选名单以进行进一步验证。其中，miR-375在哮喘中上调，而miR-297、miR-367和miR-539在COPD中与健康对照组相比上调。此外，与哮喘相比，miR-512-3p在COPD中下调，miR-517c上调。该比较显示出极好的鉴别力，呼吸细胞分泌的miR-512-3p和miR-517c的差异表达为100%，它们可以在EBC样本中定量表达，并用于区分哮喘和COPD。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of breath research BIOCHEMICAL RESEARCH METHODS-RESPIRATORY SYSTEM

CiteScore

7.60

自引率

21.10%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Breath Research is dedicated to all aspects of scientific breath research. The traditional focus is on analysis of volatile compounds and aerosols in exhaled breath for the investigation of exogenous exposures, metabolism, toxicology, health status and the diagnosis of disease and breath odours. The journal also welcomes other breath-related topics. Typical areas of interest include: Big laboratory instrumentation: describing new state-of-the-art analytical instrumentation capable of performing high-resolution discovery and targeted breath research; exploiting complex technologies drawn from other areas of biochemistry and genetics for breath research. Engineering solutions: developing new breath sampling technologies for condensate and aerosols, for chemical and optical sensors, for extraction and sample preparation methods, for automation and standardization, and for multiplex analyses to preserve the breath matrix and facilitating analytical throughput. Measure exhaled constituents (e.g. CO2, acetone, isoprene) as markers of human presence or mitigate such contaminants in enclosed environments. Human and animal in vivo studies: decoding the ''breath exposome'', implementing exposure and intervention studies, performing cross-sectional and case-control research, assaying immune and inflammatory response, and testing mammalian host response to infections and exogenous exposures to develop information directly applicable to systems biology. Studying inhalation toxicology; inhaled breath as a source of internal dose; resultant blood, breath and urinary biomarkers linked to inhalation pathway. Cellular and molecular level in vitro studies. Clinical, pharmacological and forensic applications. Mathematical, statistical and graphical data interpretation.